We provide you with 20 years of free, institutional-grade data for OVID stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of OVID. Explore the full financial landscape of OVID stock.
| Reported Date | CIK | Ticker | Type |
|---|
Ovid Therapeutics Inc(NASDAQ:OVID) 
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and ...
Website: http://www.ovidrx.com
Founded: 2014
Full Time Employees: 65
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about OVID stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.